Daily Stock Opinions and Ratings

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Opinions

Noah Blackstein, B.A., CFA Barr Laboratories BRL-N DON'T BUY Apr 10, 2002

Health sector has been under a lot of pressure. Prefers specialty pharmaceuticals.

Noah Blackstein, B.A., CFA

Unknown

Unlock Rating

$67.650

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY ON WEAKNESS

Generic drugs is a great sector. Accumulate on a gradual basis.

TOP PICK

A generic drug manufacturer. Going to continue to grow at 15/20% over the next 3/5 years. There's a number of drugs coming off patent over the next 2/3 years and this company is probably the best positioned to benefit. Good price.

BUY

Prefers the US health care stocks as they are much larger and much more seasoned. The big pharma has been a very difficult area. A generic manufacturer. As more and more drugs come off patent, this is a good way to take advantage of the increasing demand for drugs.

TOP PICK

A generic manufacturer, so unlike big pharmas that suffer when things come off, they actually benefit. Just picked up Allegra which is coming off patent. A great growth vehicle with a lot of drugs coming off patent in the next several years. Great exposure in women's health products.

TOP PICK

Barr Pharma is a generic manufacturer. Good match with a large cap drug company. Barr is a very good company. Strong balance sheet. Started buying at $47-48 range and are still buying.

TOP PICK

Generic drug manufacturer. Earnings are growing in the 20/25% range. Generics are the beneficiaries of the push to control the accelerating healthcare costs in the US. Have a good record of acquiring new generics and delivering them in a very cost effective way. No debt on the balance sheet. Great operating margins in the 35/38% range.

PAST TOP PICK

(A Top Pick Mar 15/06. Down 22%.) Lowered its guidance by $0.01 and also received a letter from the FDA denying them an extension on a patent. Feels they can continue to grow earnings in the 15/20% range. In a good buying range now.

BUY

Has come off sharply but she is still buying. There were delays in the FDA in getting some of its drugs approved. Earnings will continue to be delivered and thinks their drug will be approved. Good value.

PAST TOP PICK

(A Top Pick Sept 26/05. Up 10%.) Still likes and is continuing to buy it here. The big news is the approval of their oral contraceptive.

PAST TOP PICK

(A Top Pick Sept 26/05. Down 7%.) Still likes. Down because the Wal-Mart announcement of putting price pressures on generics. Very innovative company, introducing lots of new products. Acquiring a European company to increase penetration into Europe.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Noah Blackstein, B.A., CFA Barr Laboratories BRL-N DON'T BUY Apr 10, 2002

You might be interested:

Barr Laboratories(BRL-N)

Barr Laboratories(BRL-N)

Barr Laboratories(BRL-N)

Barr Laboratories(BRL-N)

Barr Laboratories(BRL-N)

Barr Laboratories(BRL-N)

Barr Laboratories(BRL-N)

Barr Laboratories(BRL-N)

Barr Laboratories(BRL-N)

Barr Laboratories(BRL-N)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Kim Bolton

Stockchase Insights

Jim Cramer - Mad Money

Paul Harris, CFA

The Panic-Proof Portfolio (Stockchase Research)